NanoBio Introduces Development Program To Develop Intranasal Hepatitis B Vaccine

NanoBio and the University of Michigan’s, Michigan Nanotechnology Institute for Medicine and Biological Sciences have received funding through a Phase 1 Technology Transfer (STTR) award by the National Institutes of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients.

Through this project, NanoBio and University of Michigan teams are expected to demonstrate in animals the capabilities of a nanoemulsion-based HBV vaccine to safely induce immune responses in the presence of confounding factors such as kidney failure.

Reportedly, after successful completion of the pre clinical studies funded by this STTR, NanoBio plans to conduct a FDA-approved Phase 1 clinical trial to evaluate safety, dose range, immunogenicity and preliminary efficacy against chronic HBV in humans with kidney failure.

James Baker, founder and CEO of NanoBio, said: “Currently available HBV vaccines are effective prophylactics, but lack therapeutic properties for those that are already infected.

“This new intranasal vaccine would have great value as a treatment to reduce the risk of HBV associated liver diseases and deaths globally. The vaccine is also highly stable at room temperature enabling storage without refrigeration, a factor of great importance in the developing world.”